Low-grade, Intermediate-risk Non-muscle Invasive Bladder Cancer (NMIBC)

Non-Surgical Management of Non-Muscle Invasive Bladder Cancer: Surveillance, Chemoablation, and Office-Based Approaches - Katie Murray

Moving Beyond Repeat TURBT in Recurrent NMIBC - John Sfakianos

Rethinking Recurrence Burden in Low-Grade and Intermediate-Risk NMIBC - Sarah Psutka

Intravesical Mitomycin Hydrogel: Patient-Reported Outcomes Data from OPTIMA II, ATLAS, and ENVISION - Charles Peyton

Patient-Reported Outcomes and Qualitative Insights Inform Shared Decision-Making for Mitomycin Intravesical Solution - Ruchika Talwar

ENVISION Trial Analysis: Reverse Thermal Gel with Mitomycin Outcomes by EORTC Risk Group – William Huang

Shifting From TURBT to Chemoablation in Low-Grade Intermediate-Risk NMIBC - Max Kates

Moving Beyond TURBT: Durable LG-IR NMIBC Control with Primary Chemoablation - Sandip Prasad

OPTIMA II Five-Year Data: Mitomycin Chemoablation Provides Durable Response in LG-IR-NMIBC - Neal Shore

Shifting from Surgery to Chemoablation for Low-Grade Bladder Cancer Treatment - Katie Murray

ZUSDURI™ FDA Approved for Low-Grade Intermediate-Risk Bladder Cancer - Mark Schoenberg

Expanding Treatment Options: FDA Approval of Mitomycin Intravesical Solution for Recurrent Low-Grade Intermediate-Risk NMIBC - Sandip Prasad

Management Strategies for Low-Grade Intermediate-Risk Bladder Cancer - Sarah Psutka

Refining Risk in NMIBC: Intermediate Stratification, TURBT Quality, and Emerging Options - Katie Murray